ATE347377T1 - Polymer-stabilisierte neuropeptide - Google Patents
Polymer-stabilisierte neuropeptideInfo
- Publication number
- ATE347377T1 ATE347377T1 AT00978902T AT00978902T ATE347377T1 AT E347377 T1 ATE347377 T1 AT E347377T1 AT 00978902 T AT00978902 T AT 00978902T AT 00978902 T AT00978902 T AT 00978902T AT E347377 T1 ATE347377 T1 AT E347377T1
- Authority
- AT
- Austria
- Prior art keywords
- polymer
- neuropeptides
- stabilized
- blood
- passing
- Prior art date
Links
- 108090000189 Neuropeptides Proteins 0.000 title 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15750399P | 1999-10-04 | 1999-10-04 | |
| US16658999P | 1999-11-19 | 1999-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE347377T1 true ATE347377T1 (de) | 2006-12-15 |
Family
ID=26854193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00978902T ATE347377T1 (de) | 1999-10-04 | 2000-10-04 | Polymer-stabilisierte neuropeptide |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20020013266A1 (de) |
| EP (1) | EP1221975B1 (de) |
| JP (1) | JP4027663B2 (de) |
| KR (1) | KR100619612B1 (de) |
| AT (1) | ATE347377T1 (de) |
| AU (1) | AU782298B2 (de) |
| CA (1) | CA2385533C (de) |
| DE (1) | DE60032255T2 (de) |
| ES (1) | ES2275561T3 (de) |
| MX (1) | MXPA02003176A (de) |
| WO (1) | WO2001024831A2 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100361933B1 (ko) * | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| US6458953B1 (en) * | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| MXPA02003176A (es) * | 1999-10-04 | 2002-09-30 | Shearwater Corp | Neuropeptidos estabilizados por polimero. |
| WO2001093914A2 (en) | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| CZ20033109A3 (en) | 2001-05-17 | 2004-06-16 | Applied Research Systems Ars Holding N.V. | Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| JP4838968B2 (ja) * | 2001-09-28 | 2011-12-14 | 参天製薬株式会社 | 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤 |
| CA2571292C (en) * | 2004-06-30 | 2013-05-21 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
| US8420602B2 (en) * | 2004-09-14 | 2013-04-16 | Landon C. G. Miller | Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| EP2913056A1 (de) | 2006-01-05 | 2015-09-02 | The University of Utah Research Foundation | Verfahren und Zusammensetzungen in Zusammenhang mit der Verbesserung von Eigenschaften pharmakologischer Wirkstoffe für das Nervensystem |
| PL381925A1 (pl) * | 2007-03-07 | 2008-09-15 | Andrzej W. Lipkowski | Zastosowanie peptydu i przeciwbólowy środek farmaceutyczny |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| US10540861B2 (en) * | 2007-12-20 | 2020-01-21 | Ncr Corporation | Sustained authentication of a customer in a physical environment |
| JP5827123B2 (ja) * | 2008-09-16 | 2015-12-02 | ウェルズ ファーゴ バンク ナショナル アソシエイション | 乱用の可能性が低いｐｅｇ化オピオイド |
| US20110171165A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
| US20120195847A1 (en) * | 2008-09-19 | 2012-08-02 | Nektar Therapeutics | Polymer conjugates of biphalin peptides |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| DE202009004764U1 (de) * | 2009-04-30 | 2010-09-16 | Hettich Holding Gmbh & Co. Ohg | Siphon und Möbel |
| SI2575846T1 (sl) | 2010-05-27 | 2015-09-30 | Janssen Biotech, Inc. | Peptidi, ki vežejo receptor za inzulinu podoben rastni faktor 1 |
| US8524215B2 (en) * | 2010-08-02 | 2013-09-03 | Janssen Biotech, Inc. | Absorbable PEG-based hydrogels |
| JP2014501248A (ja) | 2010-12-15 | 2014-01-20 | ニューロアジュヴァンツ，インコーポレイテッド | ニューロペプチド類似体、組成物、及び疼痛の治療方法 |
| WO2012095523A1 (en) * | 2011-01-13 | 2012-07-19 | Theralpha | Analgesic composition for transbuccal administration |
| EP2476410A1 (de) * | 2011-01-13 | 2012-07-18 | Theralpha | Analgetische Peptid enthaltende Zusammensetzung zur transbuccalen Verabreichung |
| EP3130587B1 (de) | 2014-03-31 | 2021-06-16 | NOF Corporation | Hydrophiles polymerderivat mit cyclischem benzyliden-acetal-linker |
| JP2017525678A (ja) * | 2014-07-14 | 2017-09-07 | ピーイージー バイオサイエンシーズ インコーポレイテッド | 重合エンケファリンプロドラッグ |
| CN111220676B (zh) * | 2019-11-13 | 2022-11-29 | 上海药明生物技术有限公司 | 利用毛细管电泳技术检测含聚乙二醇的蛋白质样品纯度的方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4462941A (en) * | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
| US4468383A (en) * | 1982-09-29 | 1984-08-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service | Dimeric enkephalins |
| US4518711A (en) * | 1983-05-16 | 1985-05-21 | Gibson-Stephens Institute | Conformationally constrained cyclic enkephalin analogs with delta receptor specificity |
| US4684624A (en) * | 1983-12-22 | 1987-08-04 | Yoshio Hosobuchi | Method of treating cerebral ischemia |
| IT206701Z2 (it) * | 1985-08-02 | 1987-10-01 | Gate Spa | Ventilatore assiale particolarmente per autoveicoli |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5017689A (en) * | 1989-07-06 | 1991-05-21 | Arizona Technology Development Corporation | Dynorphin analogs specific for kappa opioid receptors |
| US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| ATE164080T1 (de) * | 1990-05-10 | 1998-04-15 | Bechgaard Int Res | Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US5326751A (en) * | 1992-06-26 | 1994-07-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Enkephalin analogs |
| EP0599303A3 (de) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| AU7113594A (en) * | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5629384A (en) * | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5670477A (en) * | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5948389A (en) * | 1995-06-07 | 1999-09-07 | El Khoury & Stein, Ltd. | Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US5945510A (en) | 1997-05-21 | 1999-08-31 | University Of Maryland, Baltimore | Substantially pure zonulin, a physiological modulator of mammalian tight junctions |
| KR20010015856A (ko) * | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
| JP4078032B2 (ja) * | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル，コーポレイション | 近位の反応性基を持つポリ（エチレングリコール）誘導体 |
| DE69939036D1 (de) * | 1998-04-28 | 2008-08-14 | Serono Lab | PEG Konjugate von LHRH Analogen |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| MXPA02003176A (es) * | 1999-10-04 | 2002-09-30 | Shearwater Corp | Neuropeptidos estabilizados por polimero. |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| ES2654819T3 (es) * | 2001-10-18 | 2018-02-15 | Nektar Therapeutics | Conjugados poliméricos de antagonistas de opioides |
-
2000
- 2000-10-04 MX MXPA02003176A patent/MXPA02003176A/es active IP Right Grant
- 2000-10-04 JP JP2001527830A patent/JP4027663B2/ja not_active Expired - Lifetime
- 2000-10-04 ES ES00978902T patent/ES2275561T3/es not_active Expired - Lifetime
- 2000-10-04 CA CA002385533A patent/CA2385533C/en not_active Expired - Lifetime
- 2000-10-04 AU AU16312/01A patent/AU782298B2/en not_active Expired
- 2000-10-04 KR KR1020027003658A patent/KR100619612B1/ko not_active Expired - Lifetime
- 2000-10-04 AT AT00978902T patent/ATE347377T1/de not_active IP Right Cessation
- 2000-10-04 EP EP00978902A patent/EP1221975B1/de not_active Expired - Lifetime
- 2000-10-04 WO PCT/US2000/041070 patent/WO2001024831A2/en not_active Ceased
- 2000-10-04 DE DE60032255T patent/DE60032255T2/de not_active Expired - Lifetime
-
2001
- 2001-09-19 US US09/956,440 patent/US20020013266A1/en not_active Abandoned
- 2001-09-19 US US09/956,271 patent/US20020019340A1/en not_active Abandoned
-
2003
- 2003-01-30 US US10/354,683 patent/US20030144207A1/en not_active Abandoned
- 2003-01-30 US US10/354,879 patent/US20030139346A1/en not_active Abandoned
- 2003-08-25 US US10/647,561 patent/US8008435B2/en not_active Expired - Fee Related
-
2011
- 2011-06-28 US US13/170,760 patent/US8440623B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020032604A (ko) | 2002-05-03 |
| WO2001024831A2 (en) | 2001-04-12 |
| EP1221975B1 (de) | 2006-12-06 |
| KR100619612B1 (ko) | 2006-09-01 |
| EP1221975A2 (de) | 2002-07-17 |
| JP4027663B2 (ja) | 2007-12-26 |
| US20030139346A1 (en) | 2003-07-24 |
| ES2275561T3 (es) | 2007-06-16 |
| US8440623B2 (en) | 2013-05-14 |
| MXPA02003176A (es) | 2002-09-30 |
| CA2385533A1 (en) | 2001-04-12 |
| US8008435B2 (en) | 2011-08-30 |
| WO2001024831A9 (en) | 2002-11-14 |
| US20030144207A1 (en) | 2003-07-31 |
| WO2001024831A3 (en) | 2002-03-07 |
| AU782298B2 (en) | 2005-07-14 |
| US20020013266A1 (en) | 2002-01-31 |
| AU1631201A (en) | 2001-05-10 |
| DE60032255T2 (de) | 2007-06-28 |
| US20040038899A1 (en) | 2004-02-26 |
| JP2003511357A (ja) | 2003-03-25 |
| US20110257106A1 (en) | 2011-10-20 |
| CA2385533C (en) | 2008-03-25 |
| US20020019340A1 (en) | 2002-02-14 |
| DE60032255D1 (de) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60032255D1 (de) | Polymer-stabilisierte neuropeptide | |
| CO5540371A2 (es) | Administracion pulmonar de insulina quimicamente modificada | |
| ATE263579T1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
| NO20023315D0 (no) | G-CSF konjugater | |
| DK0973819T3 (da) | Ikke-antigene forgrenede polymerkonjugater | |
| DE60219677D1 (de) | Wasserlösliche polymerkonjugate von retinoesäure | |
| DK0510356T3 (da) | Polyethylenglycolproteinkonjugater | |
| MA25875A1 (fr) | Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques. | |
| BR0210530A (pt) | Composições farmacêuticas de drogas e poìimeros acìdicos neutralizados | |
| ATE287705T1 (de) | Wärmegellierende bioabbaubare wässrige polymerlösung | |
| PT1196443E (pt) | Conjugados de eritropoietina com polietileno glicol | |
| ES2308032T5 (es) | Derivados poliméricos de ácido maleámico y sus bioconjugados | |
| LV10907A (lv) | Interferona polietilenglikola atvasinajums | |
| NO20024891D0 (no) | Farmasöytiske sammensetninger | |
| BR122018071968B8 (pt) | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga | |
| CY1106886T1 (el) | Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων | |
| BR0007294A (pt) | Formulações farmacêuticas aperfeiçoadas | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| CY1108197T1 (el) | Βελτιωμενες φαρμακευτικες συνταγοποιησεις αναστολεων πρωτεασης hiv | |
| BR9909087A (pt) | Formulações para proteção de conjugados peg-alfa interferon | |
| WO2021222137A3 (en) | Composition of immunomodulating serpin, serp-1 | |
| DE69825769D1 (de) | Eingekapselte wasserdispergierbare perfluoroetherpolymere | |
| RU93057952A (ru) | Биологический активный макромолекулярный конъюгат, гидразинсодержащие конъюгаты полипептидов и гликополипептидов с полимерами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |